Medline Industries Inc.’s private equity sponsors, including Blackstone, Carlyle, and Hellman & Friedman, are divesting approximately 75 million Class A shares in a secondary offering valued at $3.4 billion. This follows Medline’s successful $6.26 billion IPO in December 2025, which was the largest public debut of the year. The offering allows sponsors to capitalize on a 58% stock rally since the IPO, demonstrating a strategic move to lock in gains and provide liquidity to investors in a robust healthcare private equity exit market.
- Company
- Medline Industries Inc.
- Transaction Type
- Secondary Offering / Stake Sale
- Selling Investors
- Blackstone Inc., Carlyle Group Inc., Hellman & Friedman, Abu Dhabi Investment Authority
- Shares Offered
- Approximately 75 million Class A shares
- Stake Value
- $3.4 billion
- IPO Date
- December 2025
- IPO Proceeds
- $6.26 billion
- 2025 Net Sales
- $28.4 billion
- 2025 Adjusted EBITDA
- $3.5 billion
- Post-IPO Stock Rally
- 58% (through Monday’s close prior to announcement)
- Sector
- Healthcare
New York, NY – March 3, 2026
Most “AI for Diligence” tools are lying to you. The truth is, they are just chatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:
💼 When Claude Code Marries Due Diligence!
In a move signaling a strategic liquidity event for its private equity sponsors, Medline Industries Inc. has seen its major investors launch a secondary offering of approximately 75 million Class A shares, a stake valued at around $3.4 billion based on recent market prices. This significant divestment comes on the heels of Medline’s blockbuster initial public offering (IPO) in December 2025, which raised nearly $6.3 billion and marked the largest public debut of the year in the U.S. The offering presents a clear example of private equity firms capitalizing on a strong post-IPO valuation to realize returns, a strategy increasingly observed in the current healthcare market landscape.
Investor Rationale and Market Context
The consortium of private equity firms, including Blackstone Inc., Carlyle Group Inc., and Hellman & Friedman, along with the Abu Dhabi Investment Authority, are divesting portions of their holdings. This secondary sale is a predictable follow-up for sponsors seeking to lock in gains after a successful IPO, aligning with broader trends in private equity exit strategies. As highlighted in Bain & Company’s Global Healthcare Private Equity Report 2026, 2025 was a landmark year for healthcare private equity, with exit values leaping significantly, driven by large sponsor-to-sponsor transactions and a resurgence in IPO activity. This Medline offering is positioned within a market environment where dealmakers are increasingly utilizing creative exit pathways to provide liquidity to investors.
Vista Equity Partners, a prominent technology-focused private equity firm, has also been active in monetizing its investments, demonstrating a consistent approach to value realization through various exit avenues, including sales to strategic buyers and public market listings. While Vista’s activity is primarily in the tech sector, their disciplined strategy of identifying companies with enduring market value and scaling operations resonates with the broader private equity playbook for successful exits.
Medline’s Financial Performance and IPO Success
Medline’s recent financial performance underscores the company’s robust market position. For the full year 2025, the company reported net sales of $28.4 billion, an increase of 11.5% from the prior year, with organic sales growing by 10.5%. Adjusted EBITDA for the year reached $3.5 billion, a 3.2% increase. However, net income saw a slight decrease of 3.6% to $1.2 billion, impacted by higher costs of goods sold due to tariffs and increased operating expenses, including investments in headcount and IPO-related expenditures. In the fourth quarter of 2025, net sales grew 14.8% to $7.8 billion, though net income fell 37.7% to $180 million, with Adjusted EBITDA remaining flat at $805 million.
The successful IPO in December 2025 was a pivotal moment, raising approximately $6.26 billion and becoming the largest global IPO of that year. This offering not only provided significant liquidity for its private equity backers but also strengthened Medline’s financial foundation, enabling future investments in growth initiatives. The company’s stock had seen a significant rally of 58% since its IPO through Monday’s close, contributing to the attractive valuation for this secondary offering. Despite the strong sales growth, the company’s stock experienced a slight dip in pre-market trading following the announcement of the secondary sale.
Industry Trends and Future Outlook
The Medline stake sale occurs within a dynamic healthcare M&A and private equity landscape. According to Bain & Company, 2025 saw a substantial increase in exit values, with a surge in large sponsor-to-sponsor transactions and IPOs. This trend is expected to continue into 2026, with dealmakers looking for various liquidity solutions, including continuation vehicles and sponsor-to-sponsor trades. Reports from McDermott and PwC indicate that while divestitures may continue steadily, private equity firms are increasingly focused on specialized, higher-value segments within healthcare, such as biopharma, provider services, and tech-enabled solutions. The emphasis is on companies with predictable revenue streams, strong operational infrastructure, and a clear alignment with value-based care.
The private equity consortium’s decision to divest a substantial portion of their Medline stake after the IPO highlights a successful realization of value. As Medline navigates its future as a public entity, its performance will be closely watched against industry benchmarks for private equity-backed healthcare companies aiming for sustained growth and profitability in a complex market.
